Perla Colunga
@PerlaRcp
Followers
675
Following
2K
Media
17
Statuses
326
Hematóloga, Profesor Investigadora, Hematologia en @UANL y @FMUANL 🇲🇽 interés en BMT y Linfoma
Monterrey
Joined January 2014
New publication 📢. Very exciting news about Nivo for HL over the last months, unfortunately its access is still troubling in LATAM. Here we report our center's experience with reduced doses of Nivo in r/r HL.✅73% ORR.✅43% CR .
1
7
20
RT @JCOGO_ASCO: Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in.Relapsed/Refractory Hodgkin #Lymphoma: A Systematic Review. Read the fu….
ascopubs.org
PURPOSEBlockage of PD-1 with drugs such as nivolumab (Nivo) and pembrolizumab (Pembro) has been successfully implemented in the treatment of Hodgkin lymphoma among other types of tumors. Exorbitant...
0
16
0
0
4
0
So proud of this team’s incredible work. @VaqueraH_md , always committed and truly a rising star in the field of Hematology!.
New publication🚨. Here we synthethized available evidence on the use of low-doses of nivolumab for r/r HL, an alternative not-so-rarely used in LMICs. @PerlaRcp .
3
2
18
Alejandra is one of the brightest mentees I’ve had the pleasure of working with #EBMT25 I’m incredibly proud of you @DeLasFuentes99.
So proud of my friend @DeLasFuentes99 at #EBMT25 sharing experiences from our center 👏🏾 . Congrats 🥳
0
1
11
RT @VaqueraH_md: Lymphoma docs are the best hematologists! Had a blast interchanging experiences and learning from our deluxe visits in Mon….
0
2
0
RT @VaqueraH_md: No need for slides! Amazing lectures by Dr. Malpica and Dr. Hun Ju Lee today in Monterrey 🇲🇽. #lymsm .
0
2
0
RT @WomenInLymphoma: @TheLancetHaem addressing the need for accelerating action for women´s equality. #InternationalWomensDay2025
https://t….
0
3
0
RT @VaqueraH_md: In Monterrey 🇲🇽 we are ready to start treating patients with CAR-T! What's stopping us? Mexico's sanitary agency for whate….
0
4
0
RT @Itsinmyblood92: Proud to be a hematologist trained at the best hospital in Mexico! The best mentors, inspiring people—brilliant, but ab….
0
5
0
RT @incmnszmx: El INCMNSZ felicita a la Dra. María Roberta Demichelis Gómez por su nombramiento como Jefa del Departamento de Hematología y….
0
40
0
RT @Antonio_Vga_: Should we use RIC instead of MAC when the MRD is negative in AML? .Don’t miss the chance to come and meet @morcossandino….
0
2
0
RT @yadithlopezz: I’m thrilled to present our transatlantic #PTCy study #ASH24. No matter which side of the ocean you were on 🇪🇸🇲🇽, reduced….
0
10
0
RT @morcossandino: I’m so proud of you @BloodCellsByAle My best friend got the ASH David M. Goldenberg CRTI Award.Who run the world? 🌎😜.@AS….
0
3
0
Super proud of these two. Though I couldn’t attend #ASH24 in person, I’m happy to have served as a reviewer this year and thrilled to see my team and fellows showcasing our work. See you next year!.
1
3
29
RT @GomezDLeonMD: Star fellow @BloodCellsByAle from @uanl presenting now RIC vs MAC in ALL MRDneg patients #ASH24 #Leusm #BMTsm
https://t.c….
0
5
0
RT @BroeckelmannPJ: Nice real-world data on the safety and efficacy of low-dose nivolumab from Monterrey 🇲🇽 Similarly high response rates a….
0
6
0
RT @Antonio_Vga_: Come to poster 1665 to know more about our work on how to make the most out of PD-1 inhibitors when in a LMIC with me and….
0
2
0
RT @GomezDLeonMD: You are using too much nivolumab in Hodgkin. You can use less and get more bang for your buck. @Antonio_Vga_ continues ou….
0
2
0
RT @GomezDLeonMD: Trainees: I will be at #ASH24 ASH-a-Palooza this friday. I want to meet you and talk about books, movies, music, traveli….
0
11
0
RT @SN_Oncology: Optimizing resources: low-dose nivolumab combinations in the management of relapsed/refractory #HodgkinLymphoma: https://t….
0
3
0